StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
AXDX stock opened at $1.71 on Friday. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $7.00. The firm has a market cap of $37.71 million, a PE ratio of -0.42 and a beta of 0.62. The firm’s 50 day moving average price is $1.59 and its 200-day moving average price is $1.25.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The business had revenue of $2.99 million during the quarter, compared to analysts’ expectations of $3.00 million. Equities research analysts predict that Accelerate Diagnostics will post -2.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
See Also
- Five stocks we like better than Accelerate Diagnostics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Where Do I Find 52-Week Highs and Lows?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.